Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. MU
3. ACN
4. IBM
5. DPZ
6. PRIM
7. IMNN
8. NAVN
9. DFTX
10. META

Go back to Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression
(NYSE: ANRO) Delayed: 22.93 --0 (-0%)
Previous Close $22.93    52 Week High $ 
Open $22.93    52 Week Low $ 
Day High $22.93    P/E N/A 
Day Low $22.93    EPS $ 
Volume 6,717